autoimmune disease

Bio & Pharma Celltrion wins Australian approval for eye, bone disease biosimilars

Celltrion Inc. said Wednesday it has received regulatory approval from Australia’s Therapeutic Goods Administration (TGA) for three biosimilar...

Bio & Pharma Celltrion to sell autoimmune drug Stelara biosimilar at Costco in US

South Korea’s leading biosimilar drug developer Celltrion Inc. said on Monday it is set to sell Steqeyma, a biosimilar to autoimmune disease t...

Korean Investors Samsung to invest $10 million in US-based C2N Diagnostics

Samsung Group companies will jointly invest $10 million in C2N Diagnostics LLC, a U.S.-based company specializing in blood-based Alzheimer’s d...

Bio & Pharma Celltrion wins EU approval for autoimmune disease treatment Avtozma

Celltrion Inc.’s Avtozma, a biosimilar to Roche’s autoimmune disease treatment Actemra, has won approval from the European Commission, f...

Bio & Pharma Celltrion obtains approval of Steqeyma from FDA

South Korea's Celltrion Inc. said on Wednesday it received new drug submission (NDS) approval from the Food and Drug Administration (FDA) for Steq...

Bio & Pharma Celltrion releases Steqeyma in Europe

South Korea's Celltrion Inc. said on Monday it released Steqeyma (ustekinumab) in Europe, the biosimilar of autoimmune disease treatment Stelara.T...

Bio & Pharma Celltrion's Zymfentra gets 90% distribution channel in US

South Korean biosimilar maker Celltrion Inc. said on Monday its subcutaneous injection formulation for autoimmune diseases, Zymfentra (infliximab), ...

Bio & Pharma IMBiologics transfers autoimmune disease drug tech to Huadong Pharma

South Korea's antibody-based biotech company IMBiologics announced on Friday that it signed a contract to transfer the technology of its autoimmune ...

Bio & Pharma Costco sells Celltrion's Yuflyma Low WAC in US

South Korea's Celltrion Inc. announced on Tuesday that its autoimmune disease treatment Yuflyma (Low WAC, active ingredient adalimumab) is now avail...

Bio & Pharma Celltrion gets approval of Steqeyma in Canada

South Korea’s Celltrion Inc., received new drug submission (NDS) approval from Health Canada for Steqeyma, a biosimilar of the autoimmune dise...

Bio & Pharma Celltrion to supply Remsima, Herzuma to Peru

South Korea's Celltrion Inc. announced on Thursday that it secured a contract to supply its biosimilars for autoimmune disease treatment and antican...

Bio & Pharma Samsung Bioepis gets OK to sell Stelara biosimilar in Europe

South Korea's Samsung Bioepis has received approval from the European Commission to sell Pyzchiva, a biosimilar of the autoimmune disease Stelara.&n...

Bio & Pharma Celltrion releases Remsima SC in Denmark

South Korea's Celltrion Inc. announced on Thursday that it released its autoimmune disease treatment Remsima SC (infliximab) in Denmark. Remsima SC ...

Bio & Pharma Samsung begins new drug development for rare diseases

Samsung Bioepis Co., a biosimilar development unit of South Korea’s top conglomerate Samsung Group, has begun its new drug development busines...

Bio & Pharma Reversing age possible in a decade: Harvard Prof. David Sinclair

Humans will be able to control biological age and reverse their age in 10 years with advancements in medical science and live up to around 120, abou...

Bio & Pharma Celltrion'a autoimmune disease drug Zymfentra makes US debut

South Korean biopharmaceutical giant Celltrion Inc. said on March 17 that it has launched its new autoimmune disease treatment Zymfentra in the US m...

Bio & Pharma Celltrion ships initial supply of Zymfentra to US

South Korea's Celltrion Inc. announced on Wednesday that it shipped the first supply of its subcutaneous injection type of the autoimmune disease tr...

Bio & Pharma Samsung Bioepis to supply Hadlima to US government

South Korea’s Samsung Bioepis and the US-based Organon, the local partner company of Samsung group's biopharmaceutical research and developmen...

Artificial intelligence Kakao Brain releases medical GenAI tech for free

Kakao Brain, an artificial intelligence (AI) R&D subsidiary of South Korea's Kakao Corp., announced on Tuesday that it has uploaded the Labeler ...

Bio & Pharma Celltrion to supply Remsima SC, Yuflyma to Norway

South Korea's Celltrion Inc. announced on Wednesday that it will supply its autoimmune disease treatments Remsima SC (infliximab) and Yuflyma, the...

Bio & Pharma Kakao launches AI-based blood sugar management solution

South Korea’s Kakao Healthcare Corp. has introduced an artificial intelligence-based blood sugar management solution targeting the global digi...

Bio & Pharma ToolGen gets FDA approval for TGT-001 as ODD

South Korean genome editing developer ToolGen Inc. announced on Monday that its application for orphan drug designation (ODD) of the gene correction...

Bio & Pharma SK C&C to promote AI healthcare for brain diseases

South Korea's SK C&C announced on Thursday that it signed a strategic business agreement with Neurophet, a cloud-based AI platform for brain ima...

Bio & Pharma Dong-A ST, UMass to jointly research for gene therapy

South Korea's Dong-A ST announced on Friday it has signed a joint research agreement with the University of Massachusetts (UMass) Chan Medical Schoo...

Bio & Pharma Naver-invested ichrogene enters Thai market

South Korea's digital healthcare startup ichrogene, with investment from Naver D2 Startup Factory (D2SF), entered into Thai market. Naver Corp....

Bio & Pharma Celltrion gets FDA approval for Remsima SC

South Korea's Celltrion Inc. announced on Monday it received a new drug approval for an autoimmune disease treatment Remsima SC (active ingredient i...

Bio & Pharma Celltrion Healthcare wins Remsima order in France, Italy

South Korea's Celltrion Healthcare Co. announced on Wednesday its autoimmune disease treatment Remsima (ingredient: infliximab) has won a bid for ho...

Bio & Pharma S.Korean vaccine developer Quratis eyes Iraqi market

South Korean vaccine developer Quratis Inc. on Wednesday announced its signing of a term sheet on the direction and major transaction terms of coope...

Bio & Pharma NGeneBio applies for US patent of early diagnosis tech of dementia

South Korean medical diagnostic company NGeneBio Co. announced on Thursday that it has completed the US patent application for its technology relate...

Bio & Pharma VaxCell Bio's treatment shows promise for advanced liver cancer

South Korea's VaxCell Biotherapeutics Co. on Tuesday said its treatment for advanced liver cancer under development stopped or greatly reduced the g...